CG Oncology reported Phase 3 results showing its intravesical oncolytic immunotherapy cretostimogene reduced the risk of bladder-tumor recurrence by 68% versus current medical practice in intermediate-risk non-muscle-invasive disease. The company said the therapy could shift how clinicians manage recurrence risk after initial minimally invasive surgical management. The randomized study enrolled 367 patients and evaluated recurrence outcomes while patients were monitored every three months; repeat procedures are used if cancer returns, but ongoing monitoring and repeated interventions can erode bladder function over time. The new readout adds another competitor to the bladder cancer maintenance and surveillance-adjacent ecosystem. Investors and clinicians will focus next on durability of response, subgroup analyses, and adverse-event profiles that could affect adoption, reimbursement, and the likely positioning of cretostimogene within existing intravesical treatment pathways.